Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > SCD Interview on YouTube

<< Previous

Bullboard Posts

Next >>

Comment by evenhandon Jul 04, 2023 1:06pm

186 Views

Post# 35525979

RE:SCD Interview on YouTube

Almost the same story as in the run up of a few years back. "They are ready to grow".

I have held some shares since then just to see if I can get some of my money back. A hobby stock I guess.

They are running on the fat free diet version of accutane - so let's go buy something.

Then they got cold feet cuz the market didn't like the drugs that were chosen and the whole pharma sector got hit hard. They were going to have to grind for a bit.

So these guys think they are smarter this time round and better drug pickers.

Will wait and see if they can crank up the price.